SKB500 therapy for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called SKB500, given alone or with other treatments, for people with extensive-stage small cell lung cancer that has spread. It may be an option for those who have had little or no prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a type of lung cancer called extensive-stage small cell lung cancer, meaning it has spread beyond one lung.
- You can have had no prior treatment, or up to one prior treatment for the extensive stage.
- You must be willing to provide a tumor sample (from a past biopsy or a new one) for testing.
- You must be able to care for yourself and be up and about more than half of your waking hours.
- You must not have untreated or active brain metastases that cause symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
This trial tests a new drug called SKB571 in people with advanced non-small cell lung cancer. The goal is to see if it can help shrink tumors or slow cancer growth.
This trial tests a new medication, SKB518, for people with non-small cell or small cell lung cancer who have at least one measurable tumor and are in fairly good health. It aims to see if the drug can help shrink tumors or slow the cancer's growth.
This study tests SKB565, a new injectable cancer treatment, in people with advanced solid tumors (cancer that has spread or hasn't responded to standard treatments). The trial aims to find the right dose and learn how well it works.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.